Format

Send to

Choose Destination
Haematologica. 2017 Nov;102(11):e447-e451. doi: 10.3324/haematol.2017.168930. Epub 2017 Aug 24.

The Bruton tyrosine kinase inhibitor CC-292 shows activity in mantle cell lymphoma and synergizes with lenalidomide and NIK inhibitors depending on nuclear factor-κB mutational status.

Author information

1
Hemato-Oncology Department, IDIBAPS, Barcelona, Spain.
2
CIBERONC, Barcelona, Spain.
3
Hematology Department, Hospital Clínic-IDIBAPS, Barcelona, Spain.
4
Hematopathology Unit, Pathology Department, Hospital Clinic-IDIBAPS, Barcelona, Spain.
5
Vall d'Hebron University Hospital (HUVH) and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
6
Hemato-Oncology Department, IDIBAPS, Barcelona, Spain pperez@clinic.ub.es.
PMID:
28838994
PMCID:
PMC5664406
DOI:
10.3324/haematol.2017.168930
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center